ADHD and genetic syndromes

Brain and Development

Volumn 33, Issue 6, 2011, Pages 456-461

  Lo Castro, Adriana ^a   D'Agati, Elisa ^a   Curatolo, Paolo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Attention Deficit Hyperactivity Disorder; Fragile X Syndrome; Genetic syndromes; Mental retardation; Neurofibromatosis type 1; Sexual aneuploidies; Tuberous Sclerosis Complex; Williams Syndrome

Indexed keywords

METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; DIGEORGE SYNDROME; DISEASE ASSOCIATION; FRAGILE X SYNDROME; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; KLINEFELTER SYNDROME; NEUROBIOLOGY; NEUROFIBROMATOSIS; NONHUMAN; REVIEW; SMITH MAGENIS SYNDROME; TUBEROUS SCLEROSIS; TURNER SYNDROME; WILLIAMS BEUREN SYNDROME; X LINKED ICHTHYOSIS;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; HUMANS; PHENOTYPE; SYNDROME;

EID: 79955887086     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2010.05.011     Document Type: Review

References (63)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th, text revision ed. Washington: American Psychiatric Association; 2000.
2. Steinhausen H.C. The heterogeneity of causes and courses of attention-deficit/hyperactivity disorder. Acta Psychiatr Scand 2009, 120:392-399.
3. Sharp S.I., McQuillin A., Gurling H.M. Genetics of attention-deficit-hyperactivity disorder (ADHD). Neuropharmacology 2009, 57:590-600.
4. Gizer I.R., Ficks C., Waldman I.D. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009, 126:51-90.
5. Curatolo P., Paloscia C., D'Agati E., Moavero R., Pasini A. The neurobiology of attention deficit/hyperactivity disorder. Eur J Paediatr Neurol 2009, 13:299-304.
6. Pluess M., Belsky J., Neuman R.J. Prenatal smoking and attention-deficit/hyperactivity disorder: DRD4-7R as a plasticity gene. Biol Psychiatry 2009, 66:e5-e6.
7. DasBanerjee T., Middleton F.A., Berger D.F., Lambardo J.P., Sagvolden T., Faraone S.V. A comparison of molecular alterations in environmental and genetic rat models of ADHD: a pilot study. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1554-1563.
8. Denckla M.B. ADHD: topic update. Brain Dev 2003, 25:383-389.
9. Sullivan K., Hatton D., Hammer J., et al. ADHD symptoms in children with FXS. Am J Med Genet A 2006, 140:2275-2288.
10. D'Hulst C., Kooy R.F. The GABAA receptor: a novel target for treatment of fragile X?. Trends Neurosci 2007, 30:425-431.
11. Pfeiffer B.E., Huber K.M. The state of synapses in fragile X syndrome. Neuroscientist 2009, 15:549-567.
12. Hessl D., Rivera S.M., Reiss A.L. The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment Retard Dev Disabil Res Rev 2004, 10:17-24.
13. Curia G., Papouin T., Seguela P., Avoli M. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex 2009, 19:1515-1520.
14. Repicky S., Broadie K. Metabotropic glutamate receptor-mediated use-dependent down-regulation of synaptic excitability involves the fragile X mental retardation protein. J Neurophysiol 2009, 101:672-687.
15. Waung M.W., Huber K.M. Protein translation in synaptic plasticity: mGluR-LTD, fragile X. Curr Opin Neurobiol 2009, 19:319-326.
16. Hyman S.L., Shores A., North K.N. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005, 65:1037-1044.
17. Kayl A.E., Moore B.D. Behavioral phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev 2000, 6:117-124.
18. Guo H.F., The I., Hannan F., Bernards A., Zhong Y. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science 1997, 276:795-798.
19. Silva A.J., Frankland P.W., Marowitz Z., Friedman E., Laszlo G.S., Cioffi D., et al. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet 1997, 15:281-284.
20. Costa R.M., Federov N.B., Kogan J.H., Murphy G.G., Stern J., Ohno M., et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002, 415:526-530.
21. Rosser T.L., Packer R.J. Neurocognitive dysfunction in children with neurofibromatosis type 1. Curr Neurol Neurosci Rep 2003, 3:129-136.
22. Lopes Ferraz Filho J.R., Munis M.P., Soares Souza A., Goloni-Bertollo E.M., Pavarino-Bertelli E.C. Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1. Pediatr Radiol 2008, 38:305-310.
23. Wang P.Y., Kaufmann W.E., Koth C.W., Denckla M.B., Barker P.B. Thalamic involvement in neurofibromatosis type 1: evaluation with proton magnetic resonance spectroscopic imaging. Ann Neurol 2000, 47:477-484.
24. Niklasson L., Rasmussen P., Oskarsdottir S., Gillberg C. Attention deficits in children with 22q.11 deletion syndrome. Dev Med Child Neurol 2005, 47:803-807.
25. Niklasson L., Gillberg C. The neuropsychology of 22q11 deletion syndrome. A neuropsychiatric study of 100 individuals. Res Dev Disabil 2010, 31:185-194.
26. Antshel K.M., Conchelos J., Lanzetta G., Fremont W., Kates W.R. Behavior and corpus callosum morphology relationships in velocardiofacial syndrome (22q11.2 deletion syndrome). Psychiatry Res 2005, 138:235-245.
27. Halleland H., Lundervold A.J., Halmoy A., Haavik J., Johansson S. Association between catechol O-methyltransferase (COMT) haplotypes and severity of hyperactivity symptoms in adults. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:403-410.
28. de Vries P.J., Hunt A., Bolton P.F. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur Child Adolesc Psychiatry 2007, 16:16-24.
29. Muzykewicz D.A., Newberry P., Danforth N., Halpern E.F., Thiele E.A. Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav 2007, 11:506-513.
30. Hunt A. Development, behaviour and seizures in 300 cases of tuberous sclerosis. J Intellect Disabil Res 1993, 37:41-51.
31. Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. Lancet 2008, 372:657-668.
32. O'Callaghan F.J., Harris T., Joinson C., Bolton P., Noakes M., Presdee D., et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child 2004, 89:530-533.
33. D'Agati E., Moavero R., Cerminara C., Curatolo P. Attention-deficit-hyperactivity disorder (ADHD) and tuberous sclerosis complex. J Child Neurol 2009, 24:1282-1287.
34. Smalley S.L., Kustanovich V., Minassian S.L., Stone J.L., Ogdie M.N., McGough J.J., et al. Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism. Am J Hum Genet 2002, 71:959-963.
35. Geist R.T., Gutmann D.H. The tuberous sclerosis 2 gene is expressed at high levels in the cerebellum and developing spinal cord. Cell Growth Differ 1995, 6:1477-1483.
36. Russel H.F., Wallis D., Mazzocco M.M., Moshang T., Zackai E., Zim A.R., et al. Increased prevalence of ADHD in Turner syndrome with no evidence of imprinting effects. J Pediatr Psychol 2006, 31:945-955.
37. Haberecht M.F., Menon V., Warsofsky J.S., White C.D., Dyer-Friedman J., Glover G.H., et al. Functional neuroanatomy of visuo-spatial working memory in Turner syndrome. Hum Brain Mapp 2001, 14:96-107.
38. Bruining H., Swaab H., Kas M., van Engeland H. Psychiatric characteristics in a self-selected sample of boys with Klinefelter syndrome. Pediatrics 2009, 123:e865-e870.
39. Tartaglia N., Davis S., Hench A., Nimishakavi S., Beauregard R., Reynolds A., et al. A new look at XXYY syndrome: medical and psychological features. Am J Med Genet A 2008, 146:1509-1522.
40. Strous R.D., Spivak B., Yoran-Hegesh R., Maayan R., Averbuch E., Kotler M., et al. Analysis of neurosteroid levels in attention deficit-hyperactivity disorder. Int J Neuropsychopharmacol 2001, 4:259-264.
41. Leyfer O.T., Woodruff-Borden J., Klein-Tasman B.P., Fricke J.S., Mervis C.B. Prevalence of psychiatric disorders in 4 to 16-year-olds with Williams syndrome. Am J Med Genet B Neuropsychiatr Genet 2006, 141:615-622.
42. Schubert C. The genomic basis of the Williams-Beuren syndrome. Cell Mol Life Sci 2009, 66:1178-1197.
43. Schratt G.M., Tuebing F., Nigh E.A., Kane C.G., Sabatini M.E., Kiebler M., et al. A brain-specific microRNA regulates dendritic spine development. Nature 2006, 439:283-289.
44. Meng Y., Zhang Y., Tregoubov V., Janus C., Cruz L., Jackson M., et al. Abnormal spine morphology and enhanced LTP in LIMK-1 knockout mice. Neuron 2002, 35:121-133.
45. Dai L., Bellugi U., Chen X.N., Pulst-Korenberg A.M., Jarvinen-Pasley A., Tirosh-Wagner T., et al. Is it Williams syndrome? GTF2IRD1 implicated in visual-spatial construction and GTF2I in sociability revealed by high resolution arrays. Am J Med Genet A 2009, 149:302-314.
46. Shelley B.P., Robertson M.M. The neuropsychiatry and multisystem features of the Smith-Magenis syndrome: a review. J Neuropsychiatry Clin Neurosci 2005, 17:91-97.
47. Potocki L., Bi W., Treadwell-Deering D., Carvalho C.M., Eifert A., Friedman E.M., et al. Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. Am J Hum Genet 2007, 80:633-649.
48. Carmona-Mora P., Molina J., Encina C.A., Walz K. Mouse models of genomic syndromes as tools for understanding the basis of complex traits: an example with the Smith-Magenis and the Potocki-Lupski syndromes. Curr Genomics 2009, 10:259-268.
49. Walz K., Caratini-Rivera S., Bi W., Fonseca P., Mansouri D.L., Lynch J., et al. Modeling del(17)(p11.2p11.2) and dup(17)(p11.2p11.2) contiguous gene syndromes by chromosome engineering in mice. phenotypic consequences of gene dosage imbalance. Mol Cell Biol 2003, 23:3646-3655.
50. Lonardo F., Parenti G., Luquetti D.V., Annunziata I., Della Monica M., Perone L., et al. Contiguous gene syndrome due to an interstitial deletion in Xp22.3 in a boy with ichthyosis, chondrodysplasia punctata, mental retardation and ADHD. Eur J Med Genet 2007, 50:301-308.
51. Kent L., Emerton J., Bhadravathi V., Weisblatt E., Pasco G., Willat L.R., et al. X-linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit-hyperactivity disorder, autism and social communication deficits. J Med Genet 2008, 45:519-524.
52. Davies W., Humby T., Kong W., Otter T., Burgoyne P.S., Wilkinson L.S. Converging pharmacological and genetic evidence indicates a role for steroid sulfatase in attention. Biol Psychiatry 2009, 66:360-367.
53. Park-Chung M., Malayev A., Purdy R.H., Gibbs T.T., Farb D.H. Sulfated and unsulfated steroids modulate gamma-aminobutyric acid A receptor function through distinct sites. Brain Res 1999, 830:72-87.
54. Hastings R.P., Beck A., Daley D., Hill C. Symptoms of ADHD and their correlates in children with intellectual disabilities. Res Dev Disabil 2005, 26:456-468.
55. Pearson D.A., Lacher D., Loveland K.A., Santos C.W., Faria L.P., Azzam P.N., et al. Patterns of behavioral adjustment and maladjustment in mental retardation: comparison of children with and without ADHD. Am J Ment Retard 2000, 105:236-251.
56. de Vries P., Humphrey A., McCartney D., Prather P., Bolton P., Hunt A. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatry 2005, 14:183-190.
57. Smith M.C. Optimizing therapy of seizures in children and adolescents with developmental disorders. Neurology 2006, 67:S52-S55.
58. Smoot L.C., Boothby L.A., Gillett R.C. Clinical assessment and treatment of ADHD in children. Int J Clin Pract 2007, 61:1730-1738.
59. Torres A.R., Whitney J., Gonzalez-Heydrich J. Attention deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav 2008, 12:217-233.
60. Gucuyener K., Erdemoglu A.K., Senol S., Serdaroglu A., Soysal S., Kockar A.I. Use of methylphenidate for attention-deficit-hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003, 18:109-112.
61. Wernicke J.F., Holdridge K.C., Jin L., Edison T., Zhang S., Bang M.E., et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 2007, 49:498-502.
62. Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia 2010, 51:27-36.
63. D'Hulst C., Kooy R.F. Fragile X syndrome: from molecular genetics to therapy. J Med Genet 2009, 46:577-584.